Inhibition of Neuroblastoma Cell Growth by Difluoromethylornithine (DFMO) and Bortezomib through Suppression of LIN28 and MYCN — Oak Academic Publishing
Research ArticleOpen AccessGoogle Scholar indexed
Inhibition of Neuroblastoma Cell Growth by Difluoromethylornithine (DFMO) and Bortezomib through Suppression of LIN28 and MYCN
Pediatric Oncology Research Program, Helen DeVos Children’s Hospital, Grand Rapids, MI, USA
,
Pediatric Oncology Research Program, Helen DeVos Children’s Hospital, Grand Rapids, MI, USA
,
Pediatric Oncology Research Program, Helen DeVos Children’s Hospital, Grand Rapids, MI, USA
,
Pediatric Oncology Research Program, Helen DeVos Children’s Hospital, Grand Rapids, MI, USA
,
College of Human Medicine, Michigan State University, Grand Rapids, MI, USA
1 Pediatric Oncology Research Program, Helen DeVos Children’s Hospital, Grand Rapids, MI, USA
2 Pediatric Oncology Research Program, Helen DeVos Children’s Hospital, Grand Rapids, MI, USA
3 Pediatric Oncology Research Program, Helen DeVos Children’s Hospital, Grand Rapids, MI, USA
4 Pediatric Oncology Research Program, Helen DeVos Children’s Hospital, Grand Rapids, MI, USA
5 College of Human Medicine, Michigan State University, Grand Rapids, MI, USA
Neuroblastoma (NB) is the most common childhood cancer arising from the nervous system. Many high-risk neuroblastoma (HRNB) patients develop relapse after initial response to induction treatment and overall long term survival remains poor (less than 60%), emphasizing the need for new therapeutic approaches and more effective treatments. Combination therapies present a favorable approach to improve efficacy, decrease toxicity, and reduce development of drug resistance. Difluoromethylornithine (DFMO) has shown promise in recent clinical trials as a therapeutic agent in treating HRNB. Proteasomes are known to play an important role in tumor cell growth. Bortezomib was the first proteasome inhibitor shown to have anticancer activity clinically. In this study we explore the mechanistic and therapeutic effects of the novel drug combination of DFMO and bortezomib in NB. Cell proliferation studies demonstrated synergistic inhibition of NB cell growth. Bortezomib induced cleaved caspase-3 apoptotic pathway whereas DFMO induced a cytostatic effect on NB cells. Western blot analyses demonstrated down regulation of MYCN, LIN28 and NF-kB in response to DFMO and bortezomib, pathways that are important in cancer stem cells. A decrease in ATP-per-cell when treated with combination therapy suggests inhibition of glycolytic metabolism in NB cells. DFMO as a single agent or in combination with bortezomib significantly reduced tumor growth in xenograft mice. Given the lack of effective treatments, DFMO coupled with bortezomib offers a potential new therapeutic treatment for children with NB.
Mahoney, N.R., Liu, G.T., Menacker, S.J., Wilson, M.C., Hogarty, M.D. and Maris, J.M. (2006) Pediatric Horner Syndrome: Etiologies and Roles of Imaging and Urine Studies to Detect Neuroblastoma and Other Responsible Mass Lesions. American Journal of Ophthalmology, 142, 651-659. https://doi.org/10.1016/j.ajo.2006.05.047
Park, J.R., Eggert, A. and Caron, H. (2010) Neuroblastoma: Biology, Prognosis, and Treatment. Hematology/Oncology Clinics of North America, 24, 65-86. https://doi.org/10.1016/j.hoc.2009.11.011
Matthay, K.K. (2013) Targeted Isotretinoin in Neuroblastoma: Kinetics, Genetics, or Absorption. Clinical Cancer Research, 19, 311-313. https://doi.org/10.1158/1078-0432.CCR-12-3313
Wagner, L.M. and Danks, M.K. (2009) New Therapeutic Targets for the Treatment of High-Risk Neuroblastoma. Journal of Cellular Biochemistry, 107, 46-57. https://doi.org/10.1002/jcb.22094
Pinto, N.R., Applebaum, M.A., Volchenboum, S.L., Matthay, K.K., London, W.B., Ambros, P.F., Nakagawara, A., Berthold, F., Schleiermacher, G., Park, J.R., Valteau-Couanet, D., Pearson, A.D. and Cohn, S.L. (2015) Advances in Risk Classification and Treatment Strategies for Neuroblastoma. Journal of Clinical Oncology, 33, 3008-3017. https://doi.org/10.1200/JCO.2014.59.4648
Ishii, H., Iwatsuki, M., Ieta, K., Ohta, D., Haraguchi, N., Mimori, K. and Mori, M. (2008) Cancer Stem Cells and Chemoradiation Resistance. Cancer Science, 99, 1871-1877. https://doi.org/10.1111/j.1349-7006.2008.00914.x
Zhou, B.B., Zhang, H., Damelin, M., Geles, K.G., Grindley, J.C. and Dirks, P.B. (2009) Tumour-Initiating Cells: Challenges and Opportunities for Anticancer Drug Discovery. Nature Reviews Drug Discovery, 8, 806-823. https://doi.org/10.1038/nrd2137
Fornari, C., Beccuti, M., Lanzardo, S., Conti, L., Balbo, G., Cavallo, F., Calogero, R.A. and Cordero, F. (2014) A Mathematical-Biological Joint Effort to Investigate the Tumor-Initiating Ability of Cancer Stem Cells. PLoS One, 9, e106193. https://doi.org/10.1371/journal.pone.0106193
Dontu, G., Al-Hajj, M., Abdallah, W.M., Clarke, M.F. and Wicha, M.S. (2003) Stem Cells in Normal Breast Development and Breast Cancer. Cell Proliferation, 36, 59-72. https://doi.org/10.1046/j.1365-2184.36.s.1.6.x
O'Brien, C.A., Pollett, A., Gallinger, S. and Dick, J.E. (2007) A Human Colon Cancer Cell Capable of Initiating Tumour Growth in Immunodeficient Mice. Nature, 445, 106-110. https://doi.org/10.1038/nature05372
Tirode, F., Laud-Duval, K., Prieur, A., Delorme, B., Charbord, P. and Delattre, O. (2007) Mesenchymal Stem Cell Features of Ewing Tumors. Cancer Cell, 11, 421-429.
Ross, R.A. and Spengler, B.A. (2007) Human Neuroblastoma Stem Cells. Seminars in Cancer Biology, 17, 241-247.
Malik, F., Korkaya, H., Clouthier, S.G. and Wicha, M.S. (2012) Lin28 and HER2: Two Stem Cell Regulators Conspire to Drive Aggressive Breast Cancer. Cell Cycle, 11, 2780-2781. https://doi.org/10.4161/cc.21395
Viswanathan, S.R., Powers, J.T., Einhorn, W., Hoshida, Y., Ng, T.L., Toffanin, S., O'Sullivan, M., Lu, J., Phillips, L.A., Lockhart, V.L., Shah, S.P., Tanwar, P.S., Mermel, C.H., Beroukhim, R., Azam, M., Teixeira, J., Meyerson, M., Hughes, T.P., Llovet, J.M., Radich, J., Mullighan, C.G., Golub, T.R., Sorensen, P.H. and Daley, G.Q. (2009) Lin28 Promotes Transformation and Is Associated with Advanced Human Malignancies. Nature Genetics, 41, 843-848. https://doi.org/10.1038/ng.392
Moss, E.G., Lee, R.C. and Ambros, V. (1997) The Cold Shock Domain Protein LIN-28 Controls Developmental Timing in C. Elegans and Is Regulated by the Lin-4 RNA. Cell, 88, 637-646.
Wang, T., Wang, G., Hao, D., Liu, X., Wang, D., Ning, N. and Li, X. (2015) Aberrant Regulation of the LIN28A/LIN28B and Let-7 Loop in Human Malignant Tumors and Its Effects on the Hallmarks of Cancer. Molecular Cancer, 14, 125. https://doi.org/10.1186/s12943-015-0402-5
King, C.E., Cuatrecasas, M., Castells, A., Sepulveda, A.R., Lee, J.S. and Rustgi, A.K. (2011) LIN28B Promotes Colon Cancer Progression and Metastasis. Cancer Research, 71, 4260-4268. https://doi.org/10.1158/0008-5472.can-10-4637
Kong, D., Banerjee, S., Ahmad, A., Li, Y., Wang, Z., Sethi, S. and Sarkar, F.H. (2010) Epithelial to Mesenchymal Transition Is Mechanistically Linked with Stem Cell Signatures in Prostate Cancer Cells. PLoS ONE, 5, e12445. https://doi.org/10.1371/journal.pone.0012445
Yu, F., Yao, H., Zhu, P., Zhang, X., Pan, Q., Gong, C., Huang, Y., Hu, X., Su, F., Lieberman, J. and Song, E. (2007) Let-7 Regulates Self Renewal and Tumorigenicity of Breast Cancer Cells. Cell, 131, 1109-1123.
Meirelles, K., Benedict, L.A., Dombkowski, D., Pepin, D., Preffer, F.I., Teixeira, J., Tanwar, P.S., Young, R.H., MacLaughlin, D.T., Donahoe, P.K. and Wei, X. (2012) Human Ovarian Cancer Stem/Progenitor Cells Are Stimulated by Doxorubicin But Inhibited by Mullerian Inhibiting Substance. Proceedings of the National Academy of Sciences of the United States, 109, 2358-2363. https://doi.org/10.1073/pnas.1120733109
Molenaar, J.J., Domingo-Fernandez, R., Ebus, M.E., Lindner, S., Koster, J., Drabek, K., Mestdagh, P., van Sluis, P., Valentijn, L.J., van Nes, J., Broekmans, M., Haneveld, F., Volckmann, R., Bray, I., Heukamp, L., Sprussel, A., Thor, T., Kieckbusch, K., Klein-Hitpass, L., Fischer, M., Vandesompele, J., Schramm, A., van Noesel, M.M., Varesio, L., Speleman, F., Eggert, A., Stallings, R.L., Caron, H.N., Versteeg, R. and Schulte, J.H. (2012) LIN28B Induces Neuroblastoma and Enhances MYCN Levels via Let-7 Suppression. Nature Genetics, 44, 1199-1206. https://doi.org/10.1038/ng.2436
Samal, K., Zhao, P., Kendzicky, A., Yco, L.P., McClung, H., Gerner, E., Burns, M., Bachmann, A.S. and Sholler, G. (2013) AMXT-1501, a Novel Polyamine Transport Inhibitor, Synergizes with DFMO in Inhibiting Neuroblastoma Cell Proliferation by Targeting Both Ornithine Decarboxylase and Polyamine Transport. International Journal of Cancer, 133, 1323-1333. https://doi.org/10.1002/ijc.28139
Lange, I., Geerts, D., Feith, D.J., Mocz, G., Koster, J. and Bachmann, A.S. (2014) Novel Interaction of Ornithine Decarboxylase with Sepiapterin Reductase Regulates Neuroblastoma Cell Proliferation. Journal of Molecular Biology, 426, 332-346.
Saulnier Sholler, G.L., Gerner, E.W., Bergendahl, G., MacArthur, R.B., VanderWerff, A., Ashikaga, T., Bond, J.P., Ferguson, W., Roberts, W., Wada, R.K., Eslin, D., Kraveka, J.M., Kaplan, J., Mitchell, D., Parikh, N.S., Neville, K., Sender, L., Higgins, T., Kawakita, M., Hiramatsu, K., Moriya, S.S. and Bachmann, A.S. (2015) A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma. PLoS ONE, 10, e0127246. https://doi.org/10.1371/journal.pone.0127246
Lozier, A.M., Rich, M.E., Grawe, A.P., Peck, A.S., Zhao, P., Chang, A.T., Bond, J.P. and Sholler, G.S. (2015) Targeting Ornithine Decarboxylase Reverses the LIN28/Let-7 Axis and Inhibits Glycolytic Metabolism in Neuroblastoma. Oncotarget, 6, 196-206.
Cusack, J.C., Liu, R., Houston, M., Abendroth, K., Elliott, P.J., Adams, J. and Baldwin, A.S. (2001) Enhanced Chemosensitivity to CPT-11 with Proteasome Inhibitor PS-341: Implications for Systemic Nuclear Factor-kappaB Inhibition. Cancer Research, 61, 3535-3540.
Kane, R.C., Bross, P.F., Farrell, A.T. and Pazdur, R. (2003) Velcade: U.S. FDA Approval for the Treatment of Multiple Myeloma Progressing on Prior Therapy. Oncologist, 8, 508-513. https://doi.org/10.1634/theoncologist.8-6-508
Chen, D., Frezza, M., Schmitt, S., Kanwar, J. and Dou, Q.P. (2011) Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives. Current Cancer Drug Targets, 11, 239-253. https://doi.org/10.2174/156800911794519752
Iliopoulos, D., Hirsch, H.A. and Struhl, K. (2009) An Epigenetic Switch Involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 Links Inflammation to Cell Transformation. Cell, 139, 693-706.
Michaelis, M., Fichtner, I., Behrens, D., Haider, W., Rothweiler, F., Mack, A., Cinatl, J., Doerr, H.W. and Cinatl, J. (2006) Anti-Cancer Effects of Bortezomib against Chemoresistant Neuroblastoma Cell Lines in Vitro and in Vivo. International Journal of Oncology, 28, 439-446. https://doi.org/10.3892/ijo.28.2.439
Combaret, V., Boyault, S., Iacono, I., Brejon, S., Rousseau, R. and Puisieux, A. (2008) Effect of Bortezomib on Human Neuroblastoma: Analysis of Molecular Mechanisms Involved in Cytotoxicity. Molecular Cancer, 7, 50. https://doi.org/10.1186/1476-4598-7-50
Brignole, C., Marimpietri, D., Pastorino, F., Nico, B., Di Paolo, D., Cioni, M., Piccardi, F., Cilli, M., Pezzolo, A., Corrias, M.V., Pistoia, V., Ribatti, D., Pagnan, G. and Ponzoni, M. (2006) Effect of Bortezomib on Human Neuroblastoma Cell Growth, Apoptosis, and Angiogenesis. Journal of the National Cancer Institute, 98, 1142-1157. https://doi.org/10.1093/jnci/djj309
Berenson, J.R., Matous, J., Swift, R.A., Mapes, R., Morrison, B. and Yeh, H.S. (2007) A Phase I/II Study of Arsenic Trioxide/Bortezomib/Ascorbic Acid Combination Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma. Clinical Cancer Research, 13, 1762-1768. https://doi.org/10.1158/1078-0432.ccr-06-1812
Valentiner, U., Haane, C., Nehmann, N. and Schumacher, U. (2009) Effects of Bortezomib on Human Neuroblastoma Cells in Vitro and in a Metastatic Xenograft Model. Anticancer Research, 29, 1219-1225.
Armstrong, M.B., Schumacher, K.R., Mody, R., Yanik, G.A., Opipari, A.W. and Castle, V.P. (2008) Bortezomib as a Therapeutic Candidate for Neuroblastoma. Journal of Experimental Therapeutics & Oncology, 7, 135-145.
Brodeur, G.M. (2003) Neuroblastoma: Biological Insights into a Clinical Enigma. Nature Reviews Cancer, 3, 203-216. https://doi.org/10.1038/nrc1014
Huang, M. and Weiss, W.A. (2013) Neuroblastoma and MYCN. Cold Spring Harbor Perspectives in Medicine, 3, a014415. https://doi.org/10.1101/cshperspect.a014415
Powers, J.T., Tsanov, K.M., Pearson, D.S., Roels, F., Spina, C.S., Ebright, R., Seligson, M., de Soysa, Y., Cahan, P., Theissen, J., Tu, H.C., Han, A., Kurek, K.C., LaPier, G.S., Osborne, J.K., Ross, S.J., Cesana, M., Collins, J.J., Berthold, F. and Daley, G.Q. (2016) Multiple Mechanisms Disrupt the Let-7 microRNA Family in Neuroblastoma. Nature, 535, 246-251. https://doi.org/10.1038/nature18632
Diskin, S.J., Capasso, M., Schnepp, R.W., Cole, K.A., Attiyeh, E.F., Hou, C., Diamond, M., Carpenter, E.L., Winter, C., Lee, H., Jagannathan, J., Latorre, V., Iolascon, A., Hakonarson, H., Devoto, M. and Maris, J.M. (2012) Common Variation at 6q16 within HACE1 and LIN28B Influences Susceptibility to Neuroblastoma. Nature Genetics, 44, 1126-1130. https://doi.org/10.1038/ng.2387
Paz, E.A., LaFleur, B. and Gerner, E.W. (2014) Polyamines Are Oncometabolites That Regulate the LIN28/Let-7 Pathway in Colorectal Cancer Cells. Molecular Carcinogenesis, 53, E96-E106. https://doi.org/10.1002/mc.22051
Facchini, A., Borzi, R.M., Marcu, K.B., Stefanelli, C., Olivotto, E., Goldring, M.B., Facchini, A. and Flamigni, F. (2005) Polyamine Depletion Inhibits NF-kappaB Binding to DNA and Interleukin-8 Production in Human Chondrocytes Stimulated by Tumor Necrosis Factor-Alpha. Journal of Cellular Physiology, 204, 956-963. https://doi.org/10.1002/jcp.20368
Naugler, W.E. and Karin, M. (2008) NF-kappaB and Cancer-Identifying Targets and Mechanisms. Current Opinion in Genetics & Development, 18, 19-26.
Brown, R.E., Tan, D., Taylor, J.S., Miller, M., Prichard, J.W. and Kott, M.M. (2007) Morphoproteomic Confirmation of Constitutively Activated mTOR, ERK, and NF-kappaB Pathways in High Risk Neuro-Blastoma, with Cell Cycle and Protein Analyte Correlates. Annals of Clinical & Laboratory Science, 37, 141-147.
Zhi, Y., Lu, H., Duan, Y., Sun, W., Guan, G., Dong, Q. and Yang, C. (2015) Involvement of the Nuclear Factor-kappaB Signaling Pathway in the Regulation of CXC Chemokine Receptor-4 Expression in Neuroblastoma Cells Induced by Tumor Necrosis Factor-Alpha. International Journal of Molecular Medicine, 35, 349-357.
Zhu, H., Shyh-Chang, N., Segre, A.V., Shinoda, G., Shah, S.P., Einhorn, W.S., Takeuchi, A., Engreitz, J.M., Hagan, J.P., Kharas, M.G., Urbach, A., Thornton, J.E., Triboulet, R., Gregory, R.I., Consortium, D., Investigators, M., Altshuler, D. and Daley, G.Q. (2011) The Lin28/Let-7 Axis Regulates Glucose Metabolism. Cell, 147, 81-94.
D’Angelo, R.C. and Wicha, M.S. (2010) Stem Cells in Normal Development and Cancer. Progress in Molecular Biology and Translational Science, 95, 113-158.
Warburg, O. (1956) On the Origin of Cancer Cells. Science, 123, 309-314. https://doi.org/10.1126/science.123.3191.309
Kushner, B.H., Yeung, H.W., Larson, S.M., Kramer, K. and Cheung, N.K. (2001) Extending Positron Emission Tomography Scan Utility to High-Risk Neuroblastoma: Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography as Sole Imaging Modality in Follow-Up of Patients. Journal of Clinical Oncology, 19, 3397-405. https://doi.org/10.1200/jco.2001.19.14.3397
Denko, N.C. (2008) Hypoxia, HIF1 and Glucose Metabolism in the Solid Tumour. Nature Reviews Cancer, 8, 705-713. https://doi.org/10.1038/nrc2468